CDCA Weight-Based Dose TID

Phase 3Small molecule

CDCA Weight-Based Dose TID is one of 3 small molecule programs targeting Cerebrotendinous Xanthomatosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebrotendinous XanthomatosisActive, not recruiting

Cerebrotendinous XanthomatosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Cerebrotendinous Xanthomatosis

#DrugCompanyPhaseTrials

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 2

CDCA Weight-Based Dose TID

MMirum Pharmaceuticals, Inc.

Phase 3

1 3

Chenodeoxycholic Acid

LLeadiant Biosciences, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cerebrotendinous Xanthomatosis1 trial

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

Completed·MMirum Pharmaceuticals, Inc.·Phase 3·NCT04270682·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CDCA Weight-Based Dose TID. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CDCA Weight-Based Dose TID compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CDCA Weight-Based Dose TID. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mirum Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMirum Pharmaceuticals, Inc.

CDCA Weight-Based Dose TID

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cerebrotendinous Xanthomatosis1 trial

References

Drug Info

Quick Facts

Related News